Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BOP
Singapore, Singapore
- Ownership
- Private
- Development stage
- Other
01
Overview
BOP Therapeutics is an oncology-focused biotechnology company dedicated to developing first-in-class small molecule inhibitors targeting the BOP1 protein. The company's research centers on the role of BOP1 in ribosome biogenesis and its overexpression in various gastrointestinal cancers, including colorectal and liver cancer. By inhibiting BOP1, the company aims to induce nucleolar stress and selective apoptosis in cancer cells while sparing healthy tissue. Currently in the pre-clinical stage, BOP Therapeutics is advancing its lead candidates toward IND-enabling studies to address significant unmet needs in solid tumor treatment.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on BOP.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BOP.